Matches in SemOpenAlex for { <https://semopenalex.org/work/W1701993624> ?p ?o ?g. }
- W1701993624 abstract "Background Biologics are used for the treatment of rheumatoid arthritis and many other conditions. While the efficacy of biologics has been established, there is uncertainty regarding the adverse effects of this treatment. Since important risks such as lymphomas, serious infections and tuberculosis (TB) reactivation may be more common to the biologics but occur in small numbers across the various indications, we planned to combine the results from biologics used in many conditions to obtain much needed risk estimates. Objectives To compare the potential adverse effects of tumor necrosis factor inhibitor (adalimumab, certolizumab, etanercept, golimumab, infliximab), interleukin (IL)‐1 antagonist (anakinra), IL‐6 antagonist (tocilizumab), anti‐CD28 (abatacept), and anti‐B cell (rituximab) therapy in patients with any disease condition except human immunodeficiency disease (HIV/AIDS). Methods Randomized controlled trials (RCTs), controlled clinical trials (CCTs) and open‐label extension (OLE) studies that studied one of the nine biologics for use in any indication (with the exception of HIV/AIDS) and that reported our pre‐specified adverse outcomes (serious adverse events (SAEs), withdrawals due to adverse events (AEs), total AEs, serious infections; specific AEs, namely, tuberculosis (TB) reactivation, lymphoma and congestive heart failure) were considered for inclusion. We searched The Cochrane Library, MEDLINE, and EMBASE (to January 2010). Identifying search results and data extraction were performed independently and in duplicate. For the network meta‐analysis, we performed both Bayesian mixed‐treatment comparison models and arm‐based generalized linear mixed models. Main results We included 160 RCTs with 48,676 participants and 46 extension studies with 11,954 participants. The median duration of RCTs was six months and 13 months for OLEs. Data were limited for TB reactivation, lymphoma, and congestive heart failure. Using standard dose, compared with control, biologics as a group were associated with a statistically significant higher rate of total AEs (odds ratio (OR) 1.28, 95% credible interval (CI) 1.09 to 1.50; number needed to treat to harm (NNTH) = 22, 95% confidence interval (CI) 14 to 60), withdrawals due to AEs (OR 1.47, 95% CI 1.20 to 1.86; NNTH = 26, 95% CI 15 to 58), serious infections (OR, 1.37, 95% CI 1.04 to 1.82, NNTH = 108 95% CI, 50 to 989) and TB reactivation (OR 4.68, 95% CI 1.18 to 18.60; NNTH = 681, 95% CI 143 to 14706). The rate of SAEs, lymphoma and congestive heart failure were not statistically significantly different between biologics and control treatment. Certolizumab pegol (OR 4.75, 95% CI 1.52 to 18.65; NNTH = 12, 95% CI 4 to 79) and anakinra (OR 4.05, 95% CI 1.22 to 16.84; NNTH = 14, 95% CI 4 to 181) were associated with a statistically significantly higher risk of serious infections compared with control treatment. Compared with control, certolizumab was associated with a statistically significantly higher risk of SAEs (as defined in included studies: OR 1.57, 95% CI 1.06 to 2.32; NNTH = 18, 95% CI 9 to 162). Infliximab was associated with a statistically significantly higher risk of total AEs OR 1.55, 95% CI 1.01 to 2.35; NNTH = 13, 95% CI 8 to 505) and withdrawals due to AEs compared with control (OR 2.34, 95% CI 1.40 to 4.14; NNTH = 10, 95% CI 5 to 30). The overall numbers were relatively small for indirect comparisons. Indirect comparisons revealed that certolizumab pegol was associated with a statistically significantly higher odds of serious infections compared with abatacept, adalimumab, etanercept, golimumab and rituximab; and anakinra was statistically significantly more likely than rituximab to be associated with serious infections. Certolizumab pegol was associated with a statistically significant higher odds of SAEs compared with adalimumab and abatacept. No statistically significant differences were noted between biologics in total AEs or withdrawals due to AEs in indirect comparisons. Authors' conclusions Overall, in the short term biologics were associated with statistically significantly higher rates of serious infections, TB reactivation, total AEs and withdrawals due to AEs. Serious infections included opportunistic infections as well as bacterial infections in most studies. Some biologics had a statistically higher association with certain adverse outcomes compared with control, but there was no consistency across the outcomes so caution is needed in interpreting these results. There is a need for more research regarding the long‐term safety of biologics and an urgent need for comparative safety reports of different biologics; preferably without industry involvement. National and international registries and other types of large databases are relevant sources for providing complementary evidence regarding the short‐ and longer‐term safety of biologics." @default.
- W1701993624 created "2016-06-24" @default.
- W1701993624 creator A5005171175 @default.
- W1701993624 creator A5009204856 @default.
- W1701993624 creator A5013675218 @default.
- W1701993624 creator A5017971877 @default.
- W1701993624 creator A5019980330 @default.
- W1701993624 creator A5022067453 @default.
- W1701993624 creator A5025100919 @default.
- W1701993624 creator A5026458697 @default.
- W1701993624 creator A5026942372 @default.
- W1701993624 creator A5029111075 @default.
- W1701993624 creator A5031717153 @default.
- W1701993624 creator A5036470851 @default.
- W1701993624 creator A5036883744 @default.
- W1701993624 creator A5042923202 @default.
- W1701993624 creator A5046999547 @default.
- W1701993624 creator A5053511825 @default.
- W1701993624 creator A5065455132 @default.
- W1701993624 creator A5071194530 @default.
- W1701993624 creator A5082805795 @default.
- W1701993624 creator A5083165270 @default.
- W1701993624 creator A5091567011 @default.
- W1701993624 date "2011-02-16" @default.
- W1701993624 modified "2023-10-12" @default.
- W1701993624 title "Adverse effects of biologics: a network meta-analysis and Cochrane overview" @default.
- W1701993624 cites W142190074 @default.
- W1701993624 cites W146632862 @default.
- W1701993624 cites W1486964032 @default.
- W1701993624 cites W1528268755 @default.
- W1701993624 cites W1529371040 @default.
- W1701993624 cites W1545545773 @default.
- W1701993624 cites W1550247426 @default.
- W1701993624 cites W1586324350 @default.
- W1701993624 cites W1712519246 @default.
- W1701993624 cites W1768811307 @default.
- W1701993624 cites W1782927085 @default.
- W1701993624 cites W1815214624 @default.
- W1701993624 cites W1833163659 @default.
- W1701993624 cites W1856317135 @default.
- W1701993624 cites W1881645841 @default.
- W1701993624 cites W1908888716 @default.
- W1701993624 cites W1922566561 @default.
- W1701993624 cites W1928710048 @default.
- W1701993624 cites W1947346879 @default.
- W1701993624 cites W19551277 @default.
- W1701993624 cites W1961762341 @default.
- W1701993624 cites W1964785646 @default.
- W1701993624 cites W1965630245 @default.
- W1701993624 cites W1966137955 @default.
- W1701993624 cites W1966756501 @default.
- W1701993624 cites W1966831995 @default.
- W1701993624 cites W1969692552 @default.
- W1701993624 cites W1969754850 @default.
- W1701993624 cites W1969985421 @default.
- W1701993624 cites W1972702430 @default.
- W1701993624 cites W1975137544 @default.
- W1701993624 cites W1975463338 @default.
- W1701993624 cites W1975501001 @default.
- W1701993624 cites W1979251453 @default.
- W1701993624 cites W1979364075 @default.
- W1701993624 cites W1979434114 @default.
- W1701993624 cites W1979638872 @default.
- W1701993624 cites W1980464290 @default.
- W1701993624 cites W1982176411 @default.
- W1701993624 cites W1984073706 @default.
- W1701993624 cites W1985763670 @default.
- W1701993624 cites W1986704470 @default.
- W1701993624 cites W1988315064 @default.
- W1701993624 cites W1990305566 @default.
- W1701993624 cites W1991810959 @default.
- W1701993624 cites W1994065448 @default.
- W1701993624 cites W1995228104 @default.
- W1701993624 cites W1995356102 @default.
- W1701993624 cites W1995939575 @default.
- W1701993624 cites W1996136023 @default.
- W1701993624 cites W1996389186 @default.
- W1701993624 cites W1996470340 @default.
- W1701993624 cites W1996472975 @default.
- W1701993624 cites W1997568521 @default.
- W1701993624 cites W1997816635 @default.
- W1701993624 cites W1997911453 @default.
- W1701993624 cites W1997957358 @default.
- W1701993624 cites W1999777294 @default.
- W1701993624 cites W2000500639 @default.
- W1701993624 cites W2001288327 @default.
- W1701993624 cites W2001302091 @default.
- W1701993624 cites W2004646141 @default.
- W1701993624 cites W2006154561 @default.
- W1701993624 cites W2006566716 @default.
- W1701993624 cites W2006973385 @default.
- W1701993624 cites W2007252822 @default.
- W1701993624 cites W2008716526 @default.
- W1701993624 cites W2009258522 @default.
- W1701993624 cites W2013361256 @default.
- W1701993624 cites W2013396960 @default.
- W1701993624 cites W2015215846 @default.
- W1701993624 cites W2016735282 @default.
- W1701993624 cites W2017838778 @default.
- W1701993624 cites W2018410379 @default.